Nivolumab (Opdivo) plus ipilimumab (Yervoy) in combination with two cycles of platinum-doublet chemotherapy has been added to the PBS for patients with previously untreated squamous stage IV non-small cell lung cancer (NSCLC) who are EGFR and ALK negative. The PBS listing is supported by evidence including the recently published CheckMate 9LA study which found the ...
PBS listing provides new chemo plus immunotherapy option for stage IV lung cancer
By Mardi Chapman
30 Mar 2021